Biotech M&A Surpasses $106 Billion in 2026 as Big Pharma Races to Replenish Pipelines Before Patent Cliffs 2 days ago AnaIn DealsFunding RoundsInvestmentsPartnerships
Gilead’s Bictegravir/Lenacapavir Combination Wins FDA Priority Review, PDUFA Date Set for August 2026 2 days ago AnaIn FDA ApprovalsResearch UpdatesTop Stories
Definium’s DT120 Delivers Rapid, Durable Antidepressant Effect in Phase 3 EMERGE Trial — LSD Analogue Posts Landmark MDD Results 2 days ago AnaIn Breaking NewsClinical TrialsFeatured AnalysisResearch Updates
Australia’s TGA Grants Conditional Approval to Iovance’s Lifileucel — A First for T Cell Therapy in Solid Tumour Oncology 2 days ago AnaIn BreakthroughsClinical TrialsFeatured AnalysisInnovation
FDA Approves AstraZeneca’s Truqap Combination as First Targeted Therapy for PTEN-Deficient Metastatic Prostate Cancer 2 days ago AnaIn Breaking NewsFDA ApprovalsResearch Updates
Bemdaneprocel Phase I Data Show Sustained Motor Benefits at 36 Months in Parkinson’s Disease, Advancing Case for Cell Replacement 1 week ago AnaIn Biopharma HighlightsClinical Trials
NewLimit Raises $435 Million on Evidence of Age Reversal in Human Liver Cells, Plans First Clinical Trial 1 week ago AnaIn DealsFunding RoundsVenture Capital
FDA Approves First Oral Carbapenem for Complicated Urinary Tract Infections, Ending Decades of IV Dependency 1 week ago AnaIn FDA ApprovalsResearch Updates
Neurona Therapeutics Plans Phase 3 EPIC Trial After Rezanecel Shows Durable Seizure Reduction in 31-Patient Phase 1/2 Dataset 1 week ago AnaIn Biopharma HighlightsClinical Trials
1 Biotech M&A Surpasses $106 Billion in 2026 as Big Pharma Races to Replenish Pipelines Before Patent Cliffs
2 Gilead’s Bictegravir/Lenacapavir Combination Wins FDA Priority Review, PDUFA Date Set for August 2026
3 Definium’s DT120 Delivers Rapid, Durable Antidepressant Effect in Phase 3 EMERGE Trial — LSD Analogue Posts Landmark MDD Results
4 Australia’s TGA Grants Conditional Approval to Iovance’s Lifileucel — A First for T Cell Therapy in Solid Tumour Oncology
5 FDA Approves AstraZeneca’s Truqap Combination as First Targeted Therapy for PTEN-Deficient Metastatic Prostate Cancer
